title: Are Th17 cells in the gut pathogenic or protective?
abstract: Th17 cells are abundant in multiple chronic inflammatory and autoimmune diseases. Clinical trials with antibodies to interleukin (IL)-17A, one of the Th17-cell signature cytokines, have recently reported therapeutic benefit in multiple patient populations; however, in Crohn's disease the role of Th17 cells and IL-17A appears to be more complicated. The development of different subsets of Th17 cells and their relative pathogenic activities with a focus on the gut environment will be discussed.
authors.affiliation: Department of Inflammation Research, Amgen, Seattle, WA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Symons
authors.forename: A L
authors.initials: AL
authors.lastname: Budelsky
authors.forename: J E
authors.initials: JE
authors.lastname: Towne
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology*; D041981:Gastrointestinal Tract / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D020381:Interleukin-17 / Q000276:immunology; D008213:Lymphocyte Activation; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*
chemical_list: D000906:Antibodies; D020381:Interleukin-17